PC3

This article is about the cancer cell PC3. For other uses, see PC3 (disambiguation).
Properties of common prostate cancer cell lines

PC3 (PC-3) human prostate cancer cell lines are one of the cell lines used in prostate cancer research. These cells are useful in investigating the biochemical changes in advanced prostatic cancer cells and in assessing their response to chemotherapeutic agents. Moreover, they can be used to create subcutaneous tumors in mice in order to investigate a model of the tumor environment in the context of the organism.

PC3 cell cultured in plastic plate

Description

PC3 cells have high metastatic potential compared to DU145 cells which have a moderate metastatic potential and to LNCaP cells which have low metastatic potential.[1]

PC3 cell lines were established in 1979 from bone metastasis of grade IV of prostate cancer in a 62-year-old Caucasian male.[2] These cells do not respond to androgens, glucocorticoids or fibroblast growth factors, but results suggest that the cells are influenced by epidermal growth factors.[3]

PC3 have low testosterone-5-alpha reductase and acidic phosphatase activity,[4] do not express PSA (prostate-specific antigen), and are PSMA-negative (prostate-specific membrane antigen).[5][6]

Furthermore, karyotypic analysis has shown that PC3 are near-triploid, presenting 62 chromosomes. Q-band analysis showed no Y chromosome. From a morphological point of view, electron microscopy revealed that PC3 show characteristics of poorly-differentiated adenocarcinoma. They have features common to neoplastic cells of epithelial origins, such as numerous microvilli, junctional complexes, abnormal nuclei and nucleoli, abnormal mitochondria, annulate lamellae, and lipoidal bodies.

See also

References

  1. ↑ Pulukuri SM, Gondi CS, Lakka SS, et al. (October 2005). "RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo". J. Biol. Chem. 280 (43): 36529–40. doi:10.1074/jbc.M503111200. PMC 1351057Freely accessible. PMID 16127174.
  2. ↑ Kaighn, M.E.; K.S. Narayan; Y. Ohnuki; J. F. Lechner; L.W. Jones (17 Jul 1979). "Establishment and characterization of a human prostatic carcinoma cell line (PC-3).". Invest Urol. 17 (1): 16–23. PMID 447482. Retrieved 10 August 2012.
  3. ↑ Johnston ST, Shah ET, Chopin LK, McElwain DS, Simpson MJ (June 2015). "Estimating cell diffusivity and cell proliferation rate by interpreting IncuCyte ZOOM assay data using the Fisher-Kolmogorv model". BMC Sys. Biol. 9 (38). doi:10.1186/s12918-015-0182-y.
  4. ↑ ATCC (American Type Culture Collection), retrieved 10 August 2012
  5. ↑ Ghosh, Arundhati; Xinning Wang; Eric Klein; Warren D.W. Heston (1 Feb 2005). "Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness.". Cancer Research. 65 (3): 727–31. PMID 15705868. Retrieved 1 February 2012.
  6. ↑ Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D (April 2006). "PC-3 cell line expresses androgen receptor: implications for the androgen receptor functions and regulation". FEBS Lett. 580 (9): 2294–300. doi:10.1016/j.febslet.2006.03.041. PMID 16580667.

External links


This article is issued from Wikipedia - version of the 11/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.